Patients are required to wear masks and practice physical distancing in our waiting rooms and offices. To learn more about what we are doing to keep you safe during in-office appointments, click here.

Services // Clinical Research


For all Oncology Trials
Contact Michelle Mackenzie, RN, OCN, CRC at 973-436-1755 or

For all other Studies
Contact Kelly Ritter, LPN, CCRC at 908-721-5673 or

Current active trials are listed below

Service Type Name Description
Allergy / Immunology House Dust Mite Placebo-controlled Phase III, Phase 3 COMING SOON! A One-year Placebo-controlled Phase III Trial Evaluating the Efficacy and Safety of the House Dust Mite (HDM) SLIT-tablet in Children (5-11 Years of Age) With HDM Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (NCT04145219)
Cancer Services Breast HR+/HER2- MBC, Phase 1B/3 A Phase 1B/III Study of Ipatasertib + Palbociclib and Fulvestrant vs. Placebo + Palbociclib and Fulvestrant in HR+/HER2- Locally Advanced Unresectable or Metastatic Breast Cancer (NCT04060862)
Cancer Services Hematologic Myelofibrosis, Phase 2A/2B An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post-PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor (NCT03662126)
Cancer Services Thoracic / Head & Neck Oral Mucositis H/N Cancer, Phase 3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Superoxide Dismutase Mimetic GC4419 to Reduce Severe Oral Mucositis (SOM) Associated With Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer (NCT03689712)
Cancer Services Thoracic / Head & Neck Previously Treated Advanced NSCLC, Phase 3 A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy (NCT03906071)
Cancer Services GU/Prostate Registry - Metastatic Urothelial Carcinoma, Phase None PREVAIL A Prospective, Non-Interventional Study to Assess the Prevalence of PD-L1 Expression in the First-Line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma (NCT03788746)
Cancer Services Hematologic R/R Hodgkin, Phase 2 A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classic Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma (PTCL) (NCT03947255)
Cancer Services Hematologic CLL-Previously treated, Phase 2 A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib (NCT04116437)
Cancer Services Hematologic DLBCL, Phase 2/3 A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MIND (NCT02763319)
Cancer Services Breast Neo-Adjuvant Breast, Phase 3 A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, ER+, HER2- Primary Breast Cancer — CURRENTLY ON ENROLLMENT HOLD (NCT04109066)
Cancer Services GU/Prostate Urothelial Carcinoma, Phase 2 A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) — Cisplatin Ineligible (NCT04003610)
Cancer Services Gynecologic Cervical - 2nd Line, Phase 2 A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti-CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) – RaPiDs (NCT03894215)
Cancer Services Hematologic DLBCL High Risk, Phase 3 A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naïve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™ (ENGINE Study) (NCT03263026)
Cancer Services Hematologic MCL - Untreated, Phase 1B A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma (NCT02717624)
Cancer Services Hematologic P-Vera, Phase 2A/2B A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera — Arms 1 and 3 are closed to enrollment (NCT03669965)
Cancer Services Hematologic Mantel Cell, Phase None Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents (NCT03816683)
Cancer Services Breast Met. HER2+ Breast Cancer, Phase 3 Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (NCT03975647)
Cancer Services Hematologic Untreated CLL Without del(17p) or TP53, Phase 3 A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation (NCT03836261)
Cancer Services Breast WISDOM Trial, Phase None Women Informed to Screen Depending on Measures of Risk (Wisdom Study) (WISDOM) (NCT02620852)
Cancer Services Basket Trials Solid Tumors, Phase 1/2 An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors (NCT03767348)
Cancer Services GU/Prostate Metastatic Castration-resistant Prostate Cancer, Phase 3 COMING SOON! A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX) (NCT04100018)
Cancer Services Breast HR+/HER2- MBC 2-4 prior lines, Phase 3 Phase 3 Study of Sacituzumab Govitecan vs Physician's Choice in Subjects With Hormonal Receptor-Positive Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Who Have Failed at Least 2 Prior Chemotherapy Regimens — CURRENTLY ON ENROLLMENT HOLD (NCT03901339)
Cancer Services Hematologic Follicular Lymphoma TN, Phase 3 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma (NCT02947347)
Cancer Services Hematologic FL R/R, Phase 2B A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma — 2+ prior lines (NCT02793583)
Cancer Services Hematologic Heme Malig, Phase 1/2A A Phase I/2A Open-Label, Multi-dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory CLL, SLL or T-Cell NHL — Cohort 2 (Grades 1-3A Follicular lymphoma- combination therapy with Rituximab) (NCT01994382)
Cancer Services Hematologic R/R Grades 1-3a FL, MZL, MCL, CLL/SLL, Phase 1 A Phase I Multicenter, Open-Label, Dose Escalation Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, ICP-022, in Patients with Relapsed/Refractory B-Cell Malignancies — Cohort 1 enrollment closed (NCT04014205)
Cancer Services Breast 1st line Metastatic Triple Negative BC, Phase 1B/2 Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple Negative Breast Cancer — Re-Opened to enrollment Added a weekly SGN-LIV1A dosing schedule (Part C) (NCT03310957)
Cancer Services Gastric Metastatic Cholangiocarcinoma, Phase 3 A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302) (NCT03656536)
Cancer Services Breast Neo-Adjuvant Breast, Phase 2 Randomized, Non-comparative Neoadjuvant Phase II Study in Patients with ER+/HER2- Breast Cancer > 2 cm with Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib +Anastrozole — CURRENTLY ON ENROLLMENT HOLD (NCT04075604)
Cancer Services Basket Trials Solid Tumors w/FGFR Mutation, Phase 2 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) — Cohort C is Currently on Hold (NCT03822117)
Cancer Services Hematologic CLL/SLL- R/R, Phase 3 A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT03734016)
Cancer Services Hematologic Follicular Lymphoma, Phase 2 An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma — ≥2 prior systemic therapies (NCT03332017)
Cancer Services Hematologic Multiple Myeloma, Phase None A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (NCT03901963)
Cancer Services Thoracic / Head & Neck NSCLC - Biomarker Study, Phase None COMING SOON! A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Non-Small Cell Lung Cancer (NSCLC)
Cancer Services Thoracic / Head & Neck NSCLC - Previously Treated, Phase 3 COMING SOON! A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C (NCT04303780)
Cancer Services Gynecologic Ovarian - Relapsed, Phase 2 A Phase II Randomised, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer, who have Previously Received PARP Inhibitor Maintenance Treatment (NCT04239014)
Cancer Services Hematologic AML, Phase 3 A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy (NCT02752035)
Cancer Services Hematologic Part 2 MZL Part 3 FL, Part 4 DLBCL, Phase 1B/2 An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma — >1 prior therapy ≥1 prior therapy ≥1 prior therapy (NCT02180711)